Ozempic & Mounjaro: Why You Can't Lose Weight (Metabolic Neuroscience) - Ep. 1 скачать в хорошем качестве

Ozempic & Mounjaro: Why You Can't Lose Weight (Metabolic Neuroscience) - Ep. 1

If you have ever been told that losing weight is just a matter of "eating less and moving more," or that your struggle is a failure of willpower this video is for you. For 50 years, the diet industry has ignored the most important organ in weight regulation: Your Brain. Welcome to Episode 1 of a 5-part series on Metabolic Psychiatry. As a physician and pathologist, I am breaking down the actual cellular and neurological mechanisms of weight gain. We are dismantling the shame and looking at the science of why your brain's ancient survival pathways are being hijacked by the modern environment. In this video, we cover: Why willpower is the wrong tool for weight loss (Prefrontal Cortex vs. Limbic System). The difference between your Homeostatic (survival) and Hedonic (reward) brain. Why Dopamine is NOT the "pleasure" molecule; and how ultra-processed food causes a "Reward Deficiency." The Gut-Brain Axis and the terrifying biological reality of Leptin Resistance. How chronic stress and sleep deprivation biologically force your body to store visceral fat. 👇 JOIN THE CONVERSATION: As you learn about the Homeostatic vs. Hedonic pathways in this video, which system usually 'wins' in your own life? Drop a comment below; understanding your own patterns is the first step to fixing the signal. Make sure to SUBSCRIBE and turn on notifications so you don't miss Episode 2, where we dive into the biological link between childhood trauma and endocrine reprogramming. Stay curious, stay grounded, and stay uninflamed. ⏱️ CHAPTERS / TIMESTAMPS: 0:00 - The 50-Year Weight Loss Lie 2:00 - The Two Brains: Homeostatic vs. Hedonic 4:00 - The Dopamine Myth: Why You Can't Stop Eating 6:44 - Reward Deficiency: How Modern Food Hijacks You 8:09 - Why Willpower is the Wrong Tool 11:17 - The Genetic Trigger: Why Isn't Everyone Obese? 12:27 - The Cortisol Trap: Stress & Visceral Fat 13:30 - Leptin Resistance: The Starvation Paradox 16:29 - The Perfect Storm (And How to Fix It) 22:15 - The Solution is Repair, Not Restriction 📚 SCIENTIFIC REFERENCES & CLINICAL DATA: Incentive Salience & Dopamine: Berridge, K. C., & Robinson, T. E. (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Research Reviews. Reward Deficiency & Downregulation: Volkow, N. D., et al. (2008). Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. NeuroImage. Leptin Resistance & Obesity: Crujeiras, A. B., et al. (2015). Leptin resistance in obesity: An epigenetic landscape. Life Sciences. Sleep Deprivation & Endocrine Function: Spiegel, K., et al. (2004). Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Annals of Internal Medicine. Stress, Cortisol, & Visceral Fat: Epel, E. S., et al. (2000). Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. Psychosomatic Medicine. STEP 1 (Semaglutide Weight Loss): Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. SURMOUNT-1 (Tirzepatide Weight Loss): Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. STEP-HFpEF (Heart Failure): Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023. SELECT (Cardiovascular Outcomes): Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. FLOW (Kidney Outcomes): Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. GLP-1 Physiology: Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022. Neurobiology of Reward: Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019. Body Composition (STEP 1 Analysis): McCrimmon RJ, et al. Effects of semaglutide on body composition in adults with overweight or obesity. Diabetes Obes Metab. 2021. Gallbladder Risk: He L, et al. Association of GLP-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. JAMA Intern Med. 2022. Medical Disclaimer: The content of this video is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. #WeightLoss #ozempic #Dopamine #Neuroscience #MetabolicPsychiatry #DrAminHedayat